CFO Departs Due to HR Violation; Interim CFO Appointed
Summary
MapLight Therapeutics announced the immediate separation of its Chief Financial Officer due to a human resources violation, appointing its Chief Administrative and Accounting Officer as interim CFO.
Key Events
-
Chief Financial Officer Departs
Vishwas Setia was separated as the Chief Financial Officer of MapLight Therapeutics, Inc., effective immediately.
-
Reason for Separation
The departure followed a review of a human resources violation. The company clarified it was unrelated to financial or operating results, internal controls, or clinical programs.
-
Interim CFO Appointed
Jonathan Gillis, the company's Chief Administrative and Accounting Officer, was appointed interim Chief Financial Officer and interim principal financial officer.
-
Severance Terms
Mr. Setia is not entitled to severance payment but will receive continued health coverage under COBRA for up to three months as part of a separation agreement.
Analysis
The immediate separation of a Chief Financial Officer due to a human resources violation represents a notable disruption in executive leadership. While the company explicitly stated the departure was unrelated to financial performance or controls, the underlying reason for the separation is a negative signal regarding internal conduct. The appointment of an internal Chief Administrative and Accounting Officer as interim CFO provides some continuity during this transition.
At the time of this filing, MPLT was trading at $28.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $12.24 to $33.28. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.